Century Therapeutics

Century Therapeutics

Biotechnology
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.

$266.2M

Market Cap • 10/9/2026

2018

(8 years)

Founded

2021

(5 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

1,1

P/S

—

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

1,3

EPS

—

Market Cap

Market Cap

266,2M

EV

181,1M

EV/Revenue

0

EV/EBITDA

-1,7

EV/EBIT

-1,5

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-0,2%

Total Yield

-0,2%

Payout

0%

Retained Earnings

-848,1M

Profitability

Gross Margin

—

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

0%

Capex/Revenue

0%

Capex/D&A

10,8%

Capex/OCF

-1,5%

SBC/OCF

—

% PPE

16,7%

% Goodwill

0%

ROE

—

ROIC

—

Growth

CAGR Op. Income 5Y

11%

CAGR Net Income 5Y

9,3%

CAGR EPS 5Y

-35,2%

CAGR OCF 5Y

6,6%

Leverage

N.D./EBITDA

0,8

Debt/Equity

0%

Current Ratio

8,3

Quick Ratio

7,9

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium